Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An update from Arovella Therapeutics Limited ( (AU:ALA) ) is now available.
Arovella Therapeutics Limited has issued 3,228,333 ordinary shares without disclosure under Part 6D.2 of the Corporations Act, complying with relevant provisions and confirming no excluded information needs to be disclosed. This issuance supports the company’s ongoing efforts in advancing its innovative cancer treatment platforms, potentially strengthening its market position and providing new opportunities for stakeholders.
More about Arovella Therapeutics Limited
Arovella Therapeutics Ltd is a biotechnology company focused on developing invariant natural killer T (iNKT) cell therapy to treat blood cancers and solid tumors. Their lead product, ALA-101, targets CD19, an antigen found on various cancer types, and is being developed as an allogeneic cell therapy. The company is also expanding into solid tumor treatments using CLDN18.2-targeting technology.
Average Trading Volume: 2,186,150
Technical Sentiment Signal: Sell
Current Market Cap: A$130.4M
For a thorough assessment of ALA stock, go to TipRanks’ Stock Analysis page.